The relationship between the expression of HLA-DR antigens and the HLA-DRct gene methylation was examined in systemic lupus erythematosus (SLE) 
Introduction
Systemic lupus erythematosus (SLE)' is a human autoimmune disease. Patients with SLE develop a variety of autoantibodies that react with autologous antigens including cellular, nuclear, and cytoplasmic components (1) (2) (3) (4) . A genetic predisposition to the illness and numerous immune defects found in patients with SLE have suggested that the disease may result from abnormal gene expression in components of the immune system (1, 2, 4) .
The immune recognition and response are considered to be controlled by the major histocompatibility complex (MHC) or HLA in humans. The HLA complex contains two classes ofcell surface antigens: class I and class II. The class II products are considered to play an important role in self-recognition, especially in the immune response by regulating the interaction between T cells and B cells (5) . The class II antigens, or Ia antigens, contain at least three subsets; HLA-DR, DQ, and DP (5) (6) (7) . Among them, HLA-DR molecules are dominant, composing up to 60% oftotal class II antigens at the membrane. The HLA-DR antigen consists of two different polypeptides: a-chain and (-chain. The genes encoding these polypeptides have been isolated and sequenced (8) (9) (10) (11) (12) (13) . The genomic hybridization analysis indicated that the DRa chain is encoded by a single-copy gene (12, 13) .
There is strong evidence for the involvement of the HLA in diseases (14) . Many of the HLA-DR-associated disorders are of the autoimmune type (15) . Insulin-dependent juvenile diabetes is associated with DR3, myasthenia gravis with DR3, and rheumatoid arthritis with DR4. An increased frequency of DR3 has been reported in SLE patients (6, 15) . It has been suggested that a particular HLA haplotype makes the individual either susceptible or resistant to certain diseases ( 15) . However, few surveys have studied the relationship between disease activity and the cellular expression of HLA molecules.
Vertebrate DNA contains 5-methylcytosine (mC) as a minor component, which occurs at a frequency of -1% of the total bases (16) . The mC locates primarily in the CpG dinucleotide in mammalian DNA (17) . The methylation of cytosines is a post-replicative enzymatic reaction catalyzed by DNA methyltransferase (18) . The (19) (20) (21) . It was found that the gene function is not correlated proportionally to the overall methylation level in a given genome.
The methylation at particular sites in that gene is critical for its expression (22) . In the fl-globin gene, only a few CCGG sites at the 5' extragenic region were demethylated when the gene was activated (23) . In some cases, the methylation of only one CpG site was enough to silence the gene (24, 25) . The methylation of hypoxanthine phosphoribosyltransferase locus was studied 3' region. The inactive allele showed nonuniformity and less extensive hypomethylation at the 5' cluster. It was suggested that both the methylated and unmethylated sites were important determinants of gene activity (26) .
In an attempt to understand SLE at the molecular level, we asked whether HLA-DR antigen is expressed normally in SLE and ifthe genes encoding HLA peripheral blood lymphocytes by EBV as described (27) . Briefly, peripheral blood mononuclear cells were isolated by Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, NJ) density gradient centrifugation. Collected lymphocytes were cultured at a density of 2 X 106 cells/ml. To 9 ml cell suspension, I ml culture supernatant containing EBV (B95-8) was added. After 4-8 wk, cells were subcultured, and used for further assay. Established transformed cells were designated as LC lines with appropriate numbers. Normal cell lines were marked with capital N after the number.
Determination of immunoglobulin phenotypes. Surface immunoglobulins (Ig) were determined by the conventional immunofluorescene method using fluorescein isothiocyanate-labeled anti-human y, A, or 6 (Dakopatts Lab, Uppsala, Sweden and Behringwerke, Marburg, West Germany), and by the indirect antiglobulin rosetting reaction (28) . Quantitative radioimmunoassay for the total IgG and IgM secreted from cells was performed in microplates as followings. A 50-Ml sample was incubated with 50Ml I'25l-labeled anti-human -y rabbit Ig F(ab'`) or with '25I-labeled anti-human MA rabbit Ig F(ab'`) in the well that had been coated with IgG (0.5 Mg/ml) or with IgM (0.5 Mg/ml) at 370C for 90 min.
After washing with phosphate-buffered saline (PBS) three times, the radioactivity in each well was counted by a counter. For each radioimmunoassay, a fifteen-point standard calibration curve was prepared for IgG and IgM (0.2 ng-50 Mg).
Flow cytometry analysis. An EPICS V flow cytometer (Coulter Electronics, Inc., Hialeah, FL) was used to measure cell surface antigens as described previously (29) . The antibody binding reaction was performed as described previously (29) . The murine monoclonal antibodies used were L243, P3, and 4F2. L243 reacts with nonpolymorphic regions of HLA-DR antigens (30) ; P3 is the myeloma antibody produced by the P3x63 cell line; 4F2 recognizes a 40,000-80,000 kD glycoprotein-activation antigen that is present on all tumor and EBV-transformed cell lines. P3 and 4F2 were used for negative and positive controls, respectively, together with L243 at each run. Depending upon setting and conditions of the machine, the distribution spectrum differed slightly at each run. To normalize the difference, one reference sample ofthe normal cells was included at each run.
Anti-DNA antibody assay. Total plasma (-20 ml) was used as the source of antibody. The proteins were precipitated repeatedly with 40% saturated ammonium sulfate as described (31) . Immunoglobulin (Ig) was purified by affinity chromatography of Sepharose-bound anti-human IgA, IgG, and IgM (Miles Laboratories, Inc., Elkhart, IN) as described (32) . Anti-DNA antibody activity was measured by the binding of 32P-labeled DNA. Calfthymus DNA was sheared by sonication and subjected to nick-translation with [a-32P]dNTP (Amersham Corp., Arlington Heights, IL) to give a specific activity of -I0O cpm/Mg. A 100-Ad reaction mixture contained 10 ,gg Ig and 1 Mg DNA (105 cpm) in PBS, and incubated at 370C for 30 min. The reaction mixture was diluted twofold with cold PBS and applied onto a nitrocellulose paper that was treated previously with 0.5 M KOH as described (32) . After being washed with cold PBS, the nitrocellulose paper was dried and counted for radioactivity. The antibody activity was scored on a 0-10 scale, where 0 is no DNA binding and 10 is 100% binding of input DNA under the experimental conditions. At least three different tests, each with duplicated tubes, were done and average values were calculated.
DNA and RNA hybridization. DNA was extracted from B cell lines as described (33) . DNA samples were digested with appropriate restriction endonucleases, subjected to agarose gel electrophoresis, and transferred to nitrocellulose paper as described (32) . RNA was extracted from B cells and transferred to nitrocellulose paper after agarose gel electrophoresis as described (34) . The cDNA probes were pp34RI-3 (generous gift from Professor S. Weissman, Yale University) for the HLA-DRa gene, and pHD84 (generous gift from Professor G. Attardi, California Institute of Technology) for the dihydrofolate reductase gene. The probe was nicktranslated and hybridized to sample DNAs as described (33) .
Nearest neighbor analysis. The sample DNA was subjected to nicktranslation in the presence of [a-32P]dGTP (Amersham Corp.; specific activity, 800 Ci/mmol) as described (35) . The radioactively labeled DNA was purified with repeated precipitation with ethanol and Sephadex G-50 filtration, and hydrolyzed to 3'dNMP with micrococcal nuclease and spleen phosphodiesterase as described (35) . The 3'dNMP was separated with two-dimensional thin layer chromatography, and the ratio between mC and cytosine (C) was esimated from the radioactivity in each nucleotide as described (35) .
Results
Establishment and characterization of EBV-transformed cell lines. B cell lines were established by EBV-transformation of peripheral blood lymphocytes from both SLE patients and apparently healthy donors. The immunoglobulin phenotypes were examined on the cell lines derived from 13 SLE patients, 10 control donors, and 2 patients with type I diabetes (as the disease control). Results are shown in Table I . All cell lines showed heterogeneous immunoglobulin production, indicating that EBV-transformation led to polyclonal cell activation. In all cell lines examined, surface M and 6 were dominant. Some cells expressed y and a. The immunoglobulin phenotype did not differ between SLE and control B cells. This indicates that B cell populations that were transformed by EBV are the same in SLE patients and controls. Thus, EBV-transformed cell lines provide a unique circumstance in which the biochemical aspects of SLE B cells can be compared with those of healthy controls.
Low expression of DR antigens in SLE cell lines. The expression of DR antigens was determined by monoclonal anti-DR antibody binding to B cells derived from SLE patients and control donors. Fig. 1 shows the representative patterns of DR expression analyzed by flow cytometry. First, we analyzed 12 control cell lines, which showed similar distribution spectra with a single, symmetrical peak as represented by LC63N (Fig. 1 ). Then we analyzed 46 SLE cell lines. 25 lines showed no difference from the control lines (Fig. 1 A) . We refer to these cell lines as type II. 21 cell lines showed reduced DR expression. The representative patterns are shown in Fig. 1 B and C. The spectrum Correlation ofDR expression with anti-DNA antibody quantity. To see if the reduced DR expression of B cells from SLE patients was associated with disease activity, we compared the DR-expression types with the quantity of anti-DNA antibody. After lymphocytes were isolated from patients' blood samples, immunoglobulin fractions were purified from the remaining plasma fraction, and were assayed for DNA binding activity. Fig. 2 shows the results. The relative activity of anti-DNA antibody was plotted in three groups; normal controls, type II (apparently normal DR expression), and type I (reduced DR expression). The distribution of antibody activity was heterogeneous, but the type I group appeared to contain the highest amounts of anti-DNA antibodies. The rank sum analysis indicated the P value to be <0.05 between type I and type II (P < 0.05).
Reduced amounts ofHLA-DRa mRNA. The level of DRa mRNA was analyzed by Northern blotting. Representative restilts are shown in Fig. 3 . The amounts of mRNA in three SLE cell lines were markedly reduced compared with that of control normal cells (LC63N). These cell lines showed reduced DR antigens as analyzed by flow cytometer (type I). Particularly, LC66 showed very low levels of the message, being consistent with results shown in Fig. 1 . The data indicate that the low expression of DR antigens on SLE B cell surface is the result of reduced transcriptional activity of the DR genes.
Characterization of the DRa locus and probe. It has been found that the gene expression is often inversely correlated with DNA methylation. The transcriptionally active genes are less Fig. 4 summarizes the restriction map of the CCGG sequence in the vicinity of the probe of 3.4 kb. The probe was constructed from an EcoRI-digested 3.4-kb fragment, which contained exons 2, 3, 4, and 5 of the HLADRa gene (8 Fig. 5 , MspI generated primarily a 3. 1-kb fragment. HpaII generated 3.1, 4.2, 4.5, 6.1, 7.2, and 11-kb fragments, indicating that the methylations at these sites were variable within a cell line. Since the intensity of each band is almost equal, it seems that the ratio of DNA having mC at a given CCGG site to the total DNA is similar. Although it is difficult to estimate the exact ratio from the present data, -20-30% of the total DNA seems to contain mC at an arbitrary CCGG site. In other words, a large portion of DNA contains unmethylated cytosines at any CCGG site examined.
A characteristic feature ofthe DRa locus was the uniformity of methylation in all cell lines derived from normal donors. We examined 12 control cell lines (7 Fig. 1 EB V-transformed cell lines as a material for biochemical studies. We have established more than 100 B cell lines from both SLE patients and healthy donors by EBV-transformation. The established cell lines were derived from peripheral blood lymphocytes, and could be a good source for biochemical studies, since they were available in considerable amounts at any time desired. Most B cell lines so far established were derived from peripheral blood mature lymphocytes, but recent studies have shown that EBV could transform pre-B cells originated from fetal livers (36, 37) and bone marrows (37) Reduced DR expression in SLE. Among 46 B cell lines derived from SLE patients, about half showed reduced amounts of cell surface DR antigens. In addition, the amounts of DR antigens seemed to be correlated inversely with the amounts of anti-DNA antibody at the time ofblood sampling. The decreased expression of HLA-DR antigens was also shown in peripheral blood monocytes from SLE patients (40). The involvement of DR antigens or Ia antigens in autoimmune diseases has been suggested (41-44). Self-antigens associated with self-Ia do not induce immune response through T cell reaction. When the selfIa molecule alters, the immune response occurs (43, 44) . The alteration of Ia antigens, both qualitatively and quantitatively, may occur through chronic viral infection, drugs, mutation, and gene conversion (41, 42 (41) . Whatever the mechanism is, the class II antigens play a key role in the immune regulation, and therefore, aberrant DR expression might be closely correlated with the immunoregulatory dysfunctions in SLE disease.
Two different mechanisms could result in reduced DR antigens. First, blockage of the surface antigens by autoantibodies causes an apparent reduction in DR molecules, and second, malfunctions of the DR producing system including the gene itself could account for the reduced amount of DR molecules. The first possibility is based on an observation that SLE patients produce anti-leukocyte antibodies (45, 46 DR antigens, but their structure is altered, and L243 anti-DR antibody did not bind to them; and (b) SLE cells produced reduced amounts of DR antigens. The first assumption is probable, but we favor it less: the structural mutation, if any, should occur at the whole DR molecule, since L243 reacts at the nonpolymorphic regions of DR antigen, most likely at the a-chain; no evidence has been presented showing the presence of "mutated DR antigens". The second assumption is more favorable for us, considering the reduced amounts of DRa message and the methylation patterns of DRa gene regions as discussed below.
Association ofhypermethylation with reduced DR expression. We examined the extent of methylation at at least five CCGG sites in the HLA-DRa locus. In both normal and SLE cell lines, the methylation at a given CCGG site was variable within a cell line. Since the DRa gene is a single-copy gene, a CCGG site from a single clone should be either methylated or unmethylated. The variable methylation patterns observed in normal and SLE cells could result from studying mixed populations ofcells, which might be a mixture of transformed clones in which the sites are methylated, with other clones, in which the sites are not methylated. Thus, established B cells are heterogeneous in terms of the DRa gene methylation.
A striking feature ofthe DRa gene from healthy individuals is a consistent pattern ofmethylation. B cell lines from 12 healthy persons showed exactly the same methylation pattern. This indicates that the ratio of cells with differently methylated DR genes is consistent, or well balanced in healthy persons. Striking features ofthe DRa locus from SLE patients are (a) the absence of consensus methylation pattern, and (b) hypermethylation. B cell lines from 28 SLE patients showed a variety of methylation patterns, indicating that the ratio of cells with differently methylated DR genes is patient-specific. Since the extent of methylation in SLE was higher than that in controls, cells with hypermethylated DRa gene regions could predominate in SLE patients.
The DNA hypermethylation is often associated with transcriptionally inactive genes (19) (20) (21) (22) (23) (24) (25) . In mammalian DNA, the frequency of the CCGG tetramer, of which methylation was examined in the present study, is -5% of the total methylatable CpG dinucleotide (47) . Since 60% of CpG was methylated in B cell lines, the methylation at CCGG represents only 8% of the total methylation. Thus, it is reasonable to speculate that the DRa gene contains some critical regions other than CCGG, and that their methylation might be associated with relatively high methylation levels of other sites, including CCGG. The critical sites might not be methylated in type II cells, and might be methylated in type I cells, resulting in full expression in the former and reduced expression in the latter. There is a report that might support this speculation. In DNA from T cells that do not express DRa messenger RNA (mRNA), all CCGG sites in the DRa locus examined were methylated. T cells that were infected with T cell leukemia virus (HTLV) expressed DR antigens, and the DRa locus was found to be demethylated at some CCGG sites (48 (50) and immunoglobulin genes (51) . The same sequence may occur with HLA-DR genes. In normal cells, the genes become demethylated to express DR antigens. In many SLE cells, the demethylation probably does not occur, leaving the DR genes transcriptionally silent even after B cells mature.
Peripheral blood B cells from SLE patients were found to have reduced responsiveness to B cell mitogens compared with those from normal persons (2, 52). The low response was attributed to higher spontaneous B cell proliferation in SLE patients (2) . Also, SLE patients showed the greater numbers of Igproducing cells (2, 4) . It was concluded that SLE patients have larger amounts of activated B cells in vivo than do normal persons (2, 52), i.e., SLE B cells could be more differentiated than normal cells in terms of antibody production. Nevertheless, we observed the reduced DR expression in SLE B cells, i.e., SLE B cells are less differentiated in terms of DR expression. These observations suggest that the abnormal B cell functions in SLE might occur through disturbance of a concerted regulation of genes involved in differentiation. Compared with normal cells, SLE cells might contain some genes that are suppressed and others that are activated. In lupus-prone mice, primary B cell abnormalities have been identified (53-57), and the involvement of inherent genetic factors was suggested in lupus disease (55) (56) (57) . We propose that one of factors that are involved in B cell gene regulation is DNA methylation, and that aberrant methylation/demethylation during differentiation results in dysfunctions in SLE B cells.
Finally, note that our results obtained with EBV-transformed cells might reflect the molecular aspects of limited B cell clones in vivo. First, the target of EBV seems to be restricted to certain populations of B cells. Particularly, since most SLE patients are treated with glucocorticoids (GC), the susceptibility of SLE B cells to EBV might be influenced by GC therapy. It has been reported that GC treatments lowered the Ig production in human lymphocytes (58) and promoted B cell differentiation (59) . When peripheral B cells were fractionated by density gradient centrifugation, only high density resting cells were infected. Activated low density cells were resistant to EBV infection (60) . Since the phenotype of established cell lines from both SLE and normals did not differ (Table I) , the susceptibility to EBV was the same between SLE and normal B cells. In other words, even if GC treatment affected the population ratio of B cells, as far as concerned with EBV-transformed cells, the biochemical properties should be comparable between SLE and normals in vitro. But we should keep in mind that GC might alter the ratio of B cell subsets in vivo. Second, GC treatment might influence the DR gene expression at the transcriptional and translational levels. Several lines of evidence have indicated that steroid treatment stabilized some mRNAs (61) and promoted and/or inhibited some mRNA productions (62) . We cannot exclude a possibility that the same sequence might occur in HLA-DRa mRNA production, although no evidence has so far been presented to support this idea. Further experiments are necessary to clarify these problems.
